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Background: Acute pancreatitis is the most common complication of diagnostic and therapeutic endoscopic
retrograde cholangiopancreatography (ERCP). In spite of continuing research, no pharmacologic agent capable of
effectively reducing the incidence of ERCP-induced pancreatitis has found its way into clinical practise. A number of
experimental studies suggest that intrapancreatic calcium concentrations play an important role in the initiation of
intracellular protease activation, an initiating step in the course of acute pancreatitis. Magnesium can act as a
calcium-antagonist and counteracts effects in calcium signalling. It can thereby attenuate the intracellular activation
of proteolytic digestive enzymes in the pancreas and reduces the severity of experimental pancreatitis when
administered either intravenously or as a food supplement.
Methods: We designed a randomized, double-blind, placebo-controlled phase III study to test whether the
administration of intravenous magnesium sulphate before and after ERCP reduces the incidence and the severity of
post-ERCP pancreatitis. A total of 502 adult patients with a medical indication for ERCP are to be randomized to
receive either 4930 mg magnesium sulphate (= 20 mmol magnesium) or placebo 60 min before and 6 hours after
ERCP. The incidence of clinical post-ERCP pancreatitis, hyperlipasemia, pain levels, use of analgetics and length of
hospital stay will be evaluated.
Conclusions: If magnesium sulphate is found to be effective in preventing post-ERCP pancreatitis, this inexpensive
agent with limited adverse effects could be used as a routine pharmacological prophylaxis.
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Endoscopic retrograde cholangiopancreatography (ERCP)
is a common procedure employed to treat disorders of the
biliary tract or the pancreas. In Germany around 124.000
ERCP’s (OPS 1–64, diagnostic ERC, ERP or ERCP) are
performed annually (German federal statistics bureau for
2009). The most common complication of ERCP is
procedure-related acute pancreatitis, which occurs in 2 to
9% of patients in unselected prospective studies [1]. When
an average rate of 5% is assumed, 6200 pancreatitis cases
in Germany would be triggered by prior ERCP and thus
12% of the total 53.338 in-hospital pancreatitis cases in
the country (German federal statistics bureau for 2009).
The severity of post-ERCP pancreatitis can range from
mild disease with full recovery to critical illness with pan-
creatic necrosis, multiple organ failure, prolonged
hospitalization and even death. Of all cases of post-ERCP
pancreatitis approximately 10% are severe and up to 1%
take a fatal course [2]. The national in-hospital mortality
for acute pancreatitis is 2.9% in Germany and ERCP-
induced pancreatitis would thus account for at least 180
deaths.
Efforts to reduce the incidence and severity of post-
ERCP pancreatitis have been made for more than thirty
years. So far, the search for a pharmacologic agent that
would be effective and broadly introduced into clinical
routine has been unsuccessful. Some of the pharmaco-
logic agents that have been tested for the prophylactic
administration before and during ERCP are gabexate
mesilate [3-5], octreotide [6], somatostatin [7,8], allopur-
inol [9,10], corticosteroids [11], NSAIDs [12], heparin
[13] and interleukin-10 [14]. The most promising study
suggests the routine use of diclofenac suppositories but
has demonstrated its effectiveness only in very high risk
patients [15].
One critical event for the development of acute pan-
creatitis is premature intracellular zymogen activation
leading to pancreatic autodigestion [16]. Extra- as well
as intracellular calcium concentrations have been shown
to play an important role in the initiation of intracellular
pancreatic protease activation and the onset of pancrea-
titis [17,18]. Moreover, pathological sustained calcium
signals have been shown to strongly reduce bicarbonate
secretion from pancreatic duct cells [19,20], which may
be relevant for the initiation of post-ERCP pancreatitis.
Magnesium, a critical cofactor for multiple enzymatic
reactions, acts as a natural calcium-antagonist in the
exocrine pancreas and can counteract the effect of
pathological calcium signals on premature intracellular
protease activation and cell necrosis [21]. In animal
models of acute pancreatitis Mg2+ administration not
only reduced the intrapancreatic activation of digestive
enzymes but also ameliorated the local and systemic
damage associated with the disease [22].Based on these in vitro and animal experiments we
designed a multicentre, randomized placebo-controlled
phase III trial to study the efficacy of magnesium-sulphate
in preventing the onset and reducing the severity of acute
post-ERCP pancreatitis. The “Magnesium sulphate in the
prevention of post-ERCP pancreatitis study” (MagPEP)
aims to provide robust data on the effectiveness of peri-
interventional intravenous magnesium sulphate administra-
tion in reducing the incidence and severity of post-ERCP
pancreatitis.
Methods
Trial organisation and coordination
MagPEP is designed and coordinated by the Department
of Medicine A at University Medicine Greifswald, which
is responsible for overall trial management, regulatory
affairs, statistical planning and analysis, trial registration
and reporting as well as quality assurance. Monitoring is
carried out by the Clinical Trial Coordination Centre at
Greifswald University Medicine. MagPEP will be con-
ducted as a multicentre trial in Germany and Hungary,
including (as of November 2012) ten academic medical
centres. The trial is sponsored by the University Hospital
Greifswald, represented by the CEO, and the Deutsche
Forschungsgemeinschaft (DFG), neither of which is
involved in the database management or has access to
the randomisation code.
Investigators
Patients will be recruited by the respective centres who
will commit their participation in a contractual agree-
ment with the sponsor. All investigators will be experi-
enced gastroenterologists and endoscopists. Centres
participating in the trial will have a volume load of > 400
ERCP per annum.
Data safety and monitoring board
An independent Data Safety and Monitoring Board
(DSMB) consisting of three independent experts will
evaluate the clinical research data on an ongoing basis
to assure patient safety and study integrity. The board
will monitor the trial data, particularly the safety data,
and give their advice based on the periodical reviews.
Responsibilities are recorded in a DSMB chart.
Medication supply
Study medication and placebo will be prepared and pro-
vided by the university pharmacy in Greifswald which is
ICH-GCP approved and audited by the state regulatory
authorities.
On-site monitoring
On-site monitoring of the centres will be performed
according to good clinical practice (ICH-GCP) guidelines.
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Clinical Trial Coordination Centre at Greifswald University
Medicine, clinical monitors will review all entries into CRFs
on the basis of source documents (minimum of 30% source
data verification) and perform the data management.
Ethical considerations
The final protocol has been approved by the ethics com-
mittee at the Medical Faculty of the Ernst-Moritz-Arndt-
University Greifswald on August 27th 2010 (Registration
number: FFV 04/10) and adheres to the declaration of
Helsinki, the Medical Association’s professional code of
conduct, the principles of ICH-GCP guidelines and the
Federal Data Protection Act. The trial will also be per-
formed in keeping with local legal and regulatory
requirements. The medical secrecy and the Federal Data
Protection Act will be followed. Consent to the master
ethics committee approval has been obtained from the
local ethics committees of all participating centres.
Before enrolment, each patient will be given a detailed
briefing on the nature, scope and possible consequences
of the trial by a physician and then give written informed
consent. No measures required specifically for the clin-
ical trial will be taken without valid consent having been
obtained from the patient.Study objectives
The primary objective of this study is to determine
whether intravenous magnesium sulphate administrated
before and after the intervention can reduce the inci-
dence and severity of post-ERCP pancreatitis by 50% i.e.
(from 7.4%, the incidence in Greifswald, Germany, in
2004–2005, to 3.7%). Secondary objectives include the
evaluation of (1) the severity of post-ERCP pancreatitis,
the (2) administration of analgesics, the (3) duration of
the hospital stay, the (4) lipase levels measured 6 and
24 hours after ERCP and the (5) 30-days mortality as
determined in a telephone interview 30 days after ERCP.Figure 1 Randomization and treatment flow chart of the study.Definitions
Acute post-ERCP pancreatitis is defined as the presence
of typical abdominal pain at 24 hours post ERCP in
combination with an elevation in serum lipase level to at
least three times the normal upper limit. Severity of pan-
creatitis is classified according to the 1991 Consensus
Guidelines published by Cotton et al. [23]: mild pancrea-
titis leading to a prolongation of hospitalization by up to
three days, moderate pancreatitis requiring four to ten
days of hospitalization and severe pancreatitis involving
hospitalization for more than ten days and evidence of
necrotizing pancreatitis and/or infected necrosis or
pseudocyst (fluid collection) development.Study design and setting
MagPEP is a randomized, placebo-controlled phase III
trial, in which adult patients with a clinical indication for
diagnostic or therapeutic ERCP are randomized to re-
ceive either magnesium sulphate or placebo 60 min be-
fore and 6 hours after the intervention.
The pathway by which patients are recruited and trea-
ted is shown in Figure 1.
Patients
In all of the participating academic gastroenterology depart-
ments in Germany and Hungary, all adult (≥ 18 years of
age) patients with a clinical indication for ERCP will be
screened for eligibility for the trial. Exclusion criteria are
listed in Table 1. Only patients who have not previously
undergone an ERCP will be included in the study.
Sample size considerations
Randomization of 502 patients (251 in each arm) will detect
a 50% reduction in the relative risk of post ERCP pancrea-
titis in the treatment arm as compared to the placebo arm
with 80% power (α-1 = 0.2) and a p-value of <0.05 (β-1 =
0.05). This figure assumes that the incidence of the primary
end-point without preventive measures is 7.4%, which was
the incidence of post-ERCP pancreatitis at the Department
of Medicine A of Greifswald University Medicine in the
period 2004–2005, and that the drop-out rate will be 5%.
Table 1 Exclusion ciriteria
• Previous ERCP
• Known allergy or intolerance to one of the compounds used in the
study
• Participation in another interventional trial during the previous four
weeks
• Pregnancy and breast feeding
• current acute pancreatitis
• Renal insufficiency≥ stage 4 (K/DOQI), i.e. MDRD-GFR < 30 ml/min/
1,73 m2)
• Hyperthyroidism
• Symptomatic bradycardia <35 bpm
• Atrioventricular block > 1° or other cardial conduction defects
• Myasthenia gravis
• Liver cirrhosis Child C
• Overt coagulopathy
• Kidney stone diathesis (calcium-magnesium-ammonium-phosphate
stones)
• Mental impairment, addiction or other disorders leading to the
patients inability to understand the scope and possible consequences
of a participation in a clinical trial
• Magnesium medication within 14 days before the procedure
• Inability to give informed consent
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Upon recruitment into the trial each patient will receive a
unique identification number, making all patients identifi-
able for their local treating physician throughout the study.
Only the local investigator will keep a personal list of patient
numbers and patient names in order to recover records of
the patients under his or her care after the end of the trial
or for auditing purposes. After the patient's eligibility for
randomisation has been assessed and written informed con-
sent has been obtained, he/she will be randomly assigned to
one of the two treatment arms (1:1 randomization) and re-
ceive a unique randomisation number, by which the order
in which the patients are entered at the respective centre
can be identified. Randomisation will be stratified by centre
and reported to the PI-centre by fax within 24 h. The ran-
domisation list will be kept under lock and key at the De-
partment of Medicine A in Greifswald but will be accessible
24 hours a day in case of an emergency code break. Block
randomization with blocks of four patients will be carried
out centrally in the University Pharmacy Greifswald. The
study is carried out in a double-blinded fashion.Treatment scheme
All randomized patients receive an intravenous infusion
60 min before the start and 6 hours after the end of
ERCP. To prevent adverse reactions to magnesium,
which are seen more frequently if the substance is
injected rapidly, the first infusion is given over 60 min,
the second infusion is given over 2 hours. In the magnesiumarm 500 ml NaCl 0,9% containing 10 ml magnesium
sulphate 50% (= 4930 mg magnesiumsulphate-heptahydrate;
magnesium content: 486,1 mg= 20 mmol = 40 mval) will be
administered. In the placebo arm 500 ml NaCl 0,9% + 10 ml
NaCl 0,9% will be given in the same manner. Test substance
vials are labelled with protocol and randomization number
only giving no indication as to their content.
The ERCP intervention will be carried out according
to the established clinical practice at the respective
centre and in no way differently as compared to patients
not participating in the study. After completion of the
ERCP, the endoscopist is going to fill out a questionnaire
on the details of the procedure, giving information e.g.
on the final endoscopic diagnosis, the number of pancre-
atic duct injections, cannulation difficulties, the duration
of the procedure, among other procedural details.
Six and 24 hours after ERCP patients are asked to as-
sess their pain level using a visual analogue scale and the
pain medication required and used is recorded. In
addition, a clinical examination of the abdomen is per-
formed and a blood sample is taken. To ensure blinding
the clinician in charge of the patient is not allowed to
order any tests on blood magnesium concentration un-
less in an emergency, which will lead to the exclusion of
the patient. If post-ERCP pancreatitis develops blood
samples, clinical examination, pain assessment and
documentation of pain medication is continued until the
day of discharge from the hospital.Follow-up
30 days after the ERCP all participants will be contacted
by telephone in order to determine the 30-days morbid-
ity and mortality as well as quality of life.Safety considerations
The assessment of safety will be based mainly on the fre-
quency of adverse events (AEs) and on the number of la-
boratory values falling outside of pre-determined ranges.
AEs will be summarized by presenting the number and
percentage of patients having any AEs or serious adverse
events (SAEs) and for each individual AE. Furthermore,
the most common AEs (those occurring in at least 10%
of the respective group) will be determined. Any other
information collected (e.g. severity or relatedness to
study drug) will be listed as appropriate. Laboratory data
will be summarized by presenting shift tables using nor-
mal ranges (baseline to most extreme post-baseline
value) and by presenting summary statistics of raw data
and changes from baseline values (means, medians,
standard deviations, ranges). The analysis of safety and
tolerability will be based on all patients entered into
treatment who received at least one application of the
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with exact Pearson-Clopper 95% confidence bounds.
Statistical analysis
The primary analysis will be a comparison of magnesium
versus placebo for the prevention of the primary end-
point on an ‘intention to treat’ and ‘per protocol’analysis.
Intention to treat and per protocol analyses will also be
performed for the secondary outcomes. An interim ana-
lysis for monitoring safety issues and potential power
calculation adjustments can be conducted by the data
safety monitoring committee after half the patients have
been recruited.
Discussion
We report the protocol of a prospective randomized
controlled trial to study the effectiveness of magnesium
sulphate in the prevention of post-ERCP pancreatitis,
the most important complication of diagnostic and
therapeutic ERCP. Previous in vitro experiments and
animal studies on the role of magnesium in the patho-
physiology of acute pancreatitis have suggested that
magnesium may be an effective compound to prevent
post-ERCP pancreatitis. After various but mostly inef-
fective substances have been tested in the prophylaxis of
post-ERCP pancreatitis, magnesium sulphate could have
the potential for a wide introduction into clinical prac-
tise: 1) Its administration is simple and allows for out-
patient treatment. 2) Adverse effects are rare and usually
mild [24]. 3) Contraindications are minimal. 4) Costs are
minimal and would be more then recovered by a reduc-
tion in post-ERCP pancreatitis.
The intravenous magnesium sulphate dosage used in
the MagPEP-study was chosen on the basis of previous
trials investigating the effect of magnesium sulphate on
multiple other conditions, including asthma, traumatic
brain injury, acute myocardial infarction, premature
labour, and stroke. Data from several hundred patients
have demonstrated that magnesium sulphate in the pro-
posed dosing is not likely to cause severe adverse effects,
which makes the study ethically justifiable, feasible and
safe for the participants.
Conclusions
If magnesium sulphate is found to be effective in the pre-
vention of post-ERCP pancreatitis, this inexpensive com-
pound with minimal side effects could become a routine
pharmacological prophylaxis for post-ERCP pancreatitis.
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